ArticleKidney international reports2018
Clinical Characteristics and Treatment Patterns of Children and Adults With IgA Nephropathy or IgA Vasculitis: Findings From the CureGN Study.
Open access · goldAbstract read
In one paragraph
Article in Kidney international reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers, 3 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
43citing papers in PubMed, 3 pooled it
4.9field-weighted citation impact, top 4% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
43 citing papers in PubMed, 3 syntheses or guidelines pooled it, 75 citations in OpenAlex.
- IPNA clinical practice recommendations for the diagnosis and management of children with IgA nephropathy and IgA vasculitis nephritis.Pediatric nephrology (Berlin, Germany) · 2025Guideline
- Immunosuppressive therapy for IgA nephropathy in children.The Cochrane database of systematic reviews · 2024Pooled it
- Efficacy and safety of angiotensin-converting enzyme inhibitors or angiotensin receptor blockers for IgA nephropathy in children.Pediatric nephrology (Berlin, Germany) · 2022Pooled it
- Proteinuria in adolescence.Pediatric nephrology (Berlin, Germany) · 2026Review
- IgA nephropathy: an overview of the disease, its pathophysiology, and involvement of the gut-kidney axis.Kidney international supplements · 2026Review
- IgA nephropathy management: what does the future hold?Kidney international supplements · 2026Review
- Urinary IL-18 predicts progression of IgA nephropathy.BMC nephrology · 2026Article
- Treatment practices, characteristics and outcome of immunoglobulin A nephropathy - a Swiss single center experience.Frontiers in nephrology · 2026Article
- Optimal drug treatment for children with IgA vasculitis nephritis: a systematic review and network meta-analysis.Translational pediatrics · 2025Article
- Evaluating Sibeprenlimab in IgA Nephropathy - Rationale and Baseline Data from the VISIONARY Trial.Kidney international reports · 2025Article
- IgA Vasculitis Across the Ages: Is It Time for a Precision Medicine Approach?ACR open rheumatology · 2025Review
- Recent Developments in Pediatric Nephrology.Journal of clinical medicine · 2025Article
- The incidence and prevalence of immunoglobulin A nephropathy in the United States.Clinical nephrology · 2025Article
- Efficacy of Telitacicept in treating IgA vasculitis nephritis: a two-case report.Frontiers in immunology · 2025Article
- The IgA Vasculitis Study: the evolution of a cross-sectional cohort into a trial-ready cohort.Rheumatology advances in practice · 2025Article
- Is Childhood IgA Nephropathy Different From Adult IgA Nephropathy? A Narrative Review.Canadian journal of kidney health and disease · 2025Review
- The paradox of eGFR trends and kidney failure incidence in patients without monogenic kidney disorders. Reply.The Journal of clinical investigation · 2024Article
- Nephrologists' Views on a Workflow for Returning Genetic Results to Research Participants.Kidney international reports · 2024Article
- Sparsentan ameliorates glomerular hypercellularity and inflammatory-gene networks induced by IgA1-IgG immune complexes in a mouse model of IgA nephropathy.American journal of physiology. Renal physiology · 2024Article
- A lack of KDIGO guidelines for adolescents and young adults with IgA nephropathy.Pediatric nephrology (Berlin, Germany) · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
54 authors at 20 institutions in 3 countries.
David T SelewskiDivision of Nephrology, Department of Pediatrics and Communicable Diseases, C.S. Mott Children's Hospital, University of Michigan, Ann Arbor, Michigan, USA.
Josephine M AmbruzsArkana Laboratories, Little Rock, Arkansas, USA.
Gerald B AppelDepartment of Medicine, Division of Nephrology, Columbia University College of Physicians and Surgeons, New York, New York, USA.
Andrew S BombackDepartment of Medicine, Division of Nephrology, Columbia University College of Physicians and Surgeons, New York, New York, USA.
Raed Bou MatarCenter for Pediatric Nephrology, Cleveland Clinic, Cleveland, Ohio, USA.
Yi CaiDivision of Nephrology, Helen DeVos Children's Hospital, Grand Rapids, Michigan, USA.
Daniel C CattranDivision of Nephrology, Department of Medicine, University Health Network, University of Toronto, Toronto, Ontario, Canada.
Aftab S ChishtiDivision of Nephrology, Hypertension and Renal Transplantation, University of Kentucky, Lexington, Kentucky, USA.
Vivette D D'AgatiDepartment of Pathology & Cell Biology, Columbia University Medical Center, New York, New York, USA.
Cynthia J D'Alessandri-SilvaSection of Pediatric Nephrology, Connecticut Children's Medical Center, Hartford, Connecticut, USA.
Rasheed A GbadegesinDepartment of Pediatrics, Division of Nephrology, Duke University Medical Center, Durham, North Carolina, USA.
Jonathan J HoganRenal Division, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Sandra IragorriDivision of Nephrology and Hypertension, Department of Pediatrics, Oregon Health & Science University, Portland, Oregon, USA.
J Charles JennetteDepartment of Pathology and Laboratory Medicine, University of North Carolina School of Medicine, Chapel Hill, North Carolina, USA.
Bruce A JulianDivision of Nephrology, Department of Medicine, University of Alabama at Birmingham, Birmingham, Alabama, USA.
Myda KhalidDivision of Nephrology, Department of Pediatrics, JW Riley Hospital for Children, Indiana University School of Medicine, Indianapolis, Indiana, USA.
Richard A LafayetteDivision of Nephrology and Hypertension, Stanford University, Stanford, California, USA.
Helen LiapisArkana Laboratories, Little Rock, Arkansas, USA.
Francesca LuganiPediatric Nephrology, Giannina Gasline Institute, Genova, Italy.
Sarah A MansfieldArbor Research Collaborative for Health, Ann Arbor, Michigan, USA.
Sherene MasonSection of Pediatric Nephrology, Connecticut Children's Medical Center, Hartford, Connecticut, USA.
Patrick H NachmanDivision of Renal Diseases and Hypertension, Department of Medicine, University of Minnesota, Minneapolis, MN, USA.
Cynthia C NastDepartment of Pathology, Cedars-Sinai Medical Center, Los Angeles, California, USA.
Carla M NesterDivision of Pediatric Nephrology, Dialysis and Transplantation, Stead Family Department of Pediatrics, University of Iowa, Iowa City, Iowa, USA.
Damien G NooneDivision of Nephrology, Department of Pediatrics, The Hospital for Sick Children, University Health Network, University of Toronto, Toronto, Ontario, Canada.
Jan NovakDepartment of Microbiology, University of Alabama at Birmingham, Birmingham, Alabama, USA.
Michelle M O'ShaughnessyDivision of Nephrology and Hypertension, Stanford University, Stanford, California, USA.
Heather N ReichDivision of Nephrology, Department of Medicine, University Health Network, University of Toronto, Toronto, Ontario, Canada.
Michelle N RheaultDivision of Nephrology, Department of Pediatrics, University of Minnesota Masonic Children's Hospital, Minneapolis, Minnesota, USA.
Dana V RizkDivision of Nephrology, Department of Medicine, University of Alabama at Birmingham, Birmingham, Alabama, USA.
Manish K SahaDivision of Nephrology, Department of Medicine, University of North Carolina, Chapel Hill, North Carolina, USA.
Neil S SanghaniDivision of Nephrology and Hypertension, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
C John SperatiDivision of Nephrology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Rajasree SreedharanDivision of Nephrology, Department of Pediatrics, Medical College of Wisconsin, Milwaukee, Wisconsin, USA.
Tarak SrivastavaChildren's Mercy Hospital and University of Missouri-Kansas City School of Medicine, Kansas City, Missouri, USA.
Agnieszka Swiatecka-UrbanDivision of Nephrology, Department of Pediatrics, Children's Hospital of Pittsburgh of University of Pittsburgh Medical Center, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
Katherine TwombleyDivision of Pediatric Critical Care Medicine, Medical University of South Carolina, Charleston, South Carolina, USA.
Tetyana L VasylyevaDepartment of Pediatrics, Division of Nephrology, Texas Tech University Health Sciences Center, Lubbock, Texas, USA.
Donald J WeaverDivision of Nephrology and Hypertension, Levine Children's Hospital at Carolinas Medical Center, Charlotte, North Carolina, USA.
Hong YinDivision of Pediatric Nephrology, Emory University and Children's Healthcare of Atlanta, Atlanta, Georgia, USA.
Jarcy ZeeArbor Research Collaborative for Health, Ann Arbor, Michigan, USA.
Ronald J FalkDivision of Nephrology, Department of Medicine, University of North Carolina, Chapel Hill, North Carolina, USA.
Ali G GharaviDepartment of Medicine, Division of Nephrology, Columbia University College of Physicians and Surgeons, New York, New York, USA.
Brenda W GillespieDepartment of Biostatistics, University of Michigan, Ann Arbor, Michigan, USA.
Debbie S GipsonDivision of Nephrology, Department of Pediatrics and Communicable Diseases, C.S. Mott Children's Hospital, University of Michigan, Ann Arbor, Michigan, USA.
Larry A GreenbaumDivision of Pediatric Nephrology, Emory University and Children's Healthcare of Atlanta, Atlanta, Georgia, USA.
Lawrence B HolzmanDepartment of Medicine, University of Pennsylvania Medical School, Philadelphia, Pennsylvania, USA.
Matthias KretzlerDepartment of Computational Medicine and Bioinformatics, University of Michigan School of Medicine, Ann Arbor, Michigan USA.
Bruce M RobinsonArbor Research Collaborative for Health, Ann Arbor, Michigan, USA.
William E SmoyerCenter for Clinical and Translational Research, The Research Institute at Nationwide Children's Hospital, Columbus, Ohio, USA.
Michael FlessnerDivision of Kidney, Urology, and Hematology, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland, USA.
Lisa M Guay-WoodfordCenter for Translational Science, Children's National Health System, Washington, DC, USA.
Krzysztof KirylukDepartment of Medicine, Division of Nephrology, Columbia University College of Physicians and Surgeons, New York, New York, USA.
CureGN Consortium
Columbia University · USArbor Research Collaborative for Health · USUniversity of Michigan–Ann Arbor · USUniversity of North Carolina at Chapel Hill · USUniversity of Alabama at Birmingham · USUniversity of Iowa · USArkana Laboratories · USCedars-Sinai Medical Center · USChildren's National · USEmory University · USStanford University · USUniversity Health Network · CAChildren's Hospital of Pittsburgh · USCleveland Clinic · USColumbia University Irving Medical Center · USConnecticut Children's Medical Center · USC. S. Mott Children's Hospital · USHospital of the University of Pennsylvania · USIstituto Giannina Gaslini · ITJohns Hopkins Medicine · US
Funding
CureGNU24DK100845 · NIDDK · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI CRYSTAL A. GADEGBEKU, Laura H Mariani · 2019 to 2026
$12.1MThe Columbia PCC for CureGN: the Cure Glomerulonephropathy networkU01DK100876 · NIDDK · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI Andrew Stephen Bomback, ALI G GHARAVI · 2019 to 2026
$8.5MCureGN-Penn PCCU01DK100846 · NIDDK · UNIVERSITY OF PENNSYLVANIA · PI LAWRENCE B. HOLZMAN · 2019 to 2026
$8.3MGDPrimeUM1DK100845 · NIDDK · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI GIPSON, DEBBIE S, KRETZLER, MATTHIAS · 2013 to 2018
$6.4MPrimary Outcomes in Glomerulonephritis Study (PROGRESS)UM1DK100846 · NIDDK · UNIVERSITY OF PENNSYLVANIA · PI HOLZMAN, LAWRENCE B. · 2013 to 2018
$5.8MIntegrative Proteomics & Metabolomics for Pediatric Glomerula Disease BiomarkersUM1DK100866 · NIDDK · RESEARCH INST NATIONWIDE CHILDREN'S HOSP · PI GREENBAUM, LAURENCE A, SMOYER, WILLIAM E · 2013 to 2018
$5.5MAdvancing Clinical Research in Primary Glomerular Diseases (UM1)UM1DK100876 · NIDDK · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI GHARAVI, ALI G · 2013 to 2018
$4.8MGDCN Clinical Center-Advancing Clinical Research in Primary Glomerular DiseasesUM1DK100867 · NIDDK · UNIV OF NORTH CAROLINA CHAPEL HILL · PI FALK, RONALD J · 2013 to 2018
$4.0MNIDDK NIH HHS U01 DK100846NIDDK NIH HHS U01 DK100876NIDDK NIH HHS U24 DK100845NIDDK NIH HHS UM1 DK100845NIDDK NIH HHS UM1 DK100846NIDDK NIH HHS UM1 DK100866NIDDK NIH HHS UM1 DK100867NIDDK NIH HHS UM1 DK100876
Abstract
introductionThe Cure Glomerulonephropathy Network (CureGN) is a 66-center longitudinal observational study of patients with biopsy-confirmed minimal change disease, focal segmental glomerulosclerosis, membranous nephropathy, or IgA nephropathy (IgAN), including IgA vasculitis (IgAV). This study describes the clinical characteristics and treatment patterns in the IgA cohort, including comparisons between IgAN versus IgAV and adult versus pediatric patients.
methodsPatients with a diagnostic kidney biopsy within 5 years of screening were eligible to join CureGN. This is a descriptive analysis of clinical and treatment data collected at the time of enrollment.
resultsA total of 667 patients (506 IgAN, 161 IgAV) constitute the IgAN/IgAV cohort (382 adults, 285 children). At biopsy, those with IgAV were younger (13.0 years vs. 29.6 years,
conclusionThis report highlights clinical differences between IgAV and IgAN and between children and adults with these diagnoses. We identified differences in treatment with immunosuppressive therapies by disease type. This description of baseline characteristics will serve as a foundation for future CureGN studies.
Indexed as
glomerulonephritisHenoch-Schönlein purpura (HSP)IgA nephropathy (IgAN)IgA vasculitis (IgAV)
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.